

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**信銘生命科技集團有限公司**  
**Aceso Life Science Group Limited**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 00474)**

**MAJOR TRANSACTION — PURCHASE OF BONDS  
GRANT OF WAIVER FROM STRICT COMPLIANCE  
WITH RULE 14.41(A) OF THE LISTING RULES**

Reference is made to the joint announcement jointly published by Aceso Life Science Group Limited (the “**Company**”) and HTICI on 22 June 2022 in relation to the major transaction of the Company relating to the Bonds Purchase (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

As the Bonds Purchase was approved by way of written shareholders’ approval, pursuant to Rule 14.41(a) of the Listing Rules, a circular of the Company (the “**Circular**”) containing, among other information, further details of the Bonds Purchase and other information as required under the Listing Rules must be despatched within 15 business days after publication of the Announcement. The Company has applied to the Stock Exchange for a waiver from strict compliance with Rule 14.41(a) of the Listing Rules (the “**Waiver**”) as additional time is required to prepare and finalize, among other things, the relevant financial information, including but not limited to the indebtedness statement of the Company, for inclusion in the Circular.

The Company announces that the Stock Exchange has on 14 July 2022 granted the Waiver to the Company on the condition that the Company will despatch the Circular to the shareholders of the Company on or before 24 August 2022.

By order of the board of directors of  
**Aceso Life Science Group Limited**  
**Fok Chi Tak**  
*Executive Director*

Hong Kong, 14 July 2022

*As at the date of this announcement, the board of directors of the Company comprises three executive directors, namely Mr. Xu Haiying, Dr. Zhiliang Ou, J.P. (Australia) and Mr. Fok Chi Tak; and three independent non-executive directors, namely Mr. Chan Ming Sun Jonathan, Mr. Lam Kwan Sing and Mr. Mak Yiu Tong.*